It was long used as off-label in the treatment of AML, and the first FLT3 inhibitor to be tested in post allo-HCT setting in multiple case series, then investigated in phase I trial, retrospective and registry-based studies [34,35,36,37]. Here, FLT3 is linked to acute myeloid leukemia.